Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer

Get Permission

Patients with metastatic breast cancer who took part in a 9-month structured exercise program reported less fatigue and an improved quality of life compared to those who did not participate in the exercise program, according to results from the PREFERABLE-EFFECT trial presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS02-10).

Breast cancer and its treatments can cause side effects, such as fatigue, nausea, pain, and shortness of breath, which can decrease a patient’s health-related quality of life. For patients with metastatic disease, optimizing the ability to function is crucial, explained study presenter Anne May, PhD, Professor at the Julius Center for Health Sciences and Primary Care at the University Medical Center, Utrecht, the Netherlands.

“Optimizing quality of life is, of course, important for everybody, but especially for patients living with metastatic disease who undergo continuous treatment,” Dr. May said. “By improving quality of life through enhanced symptom management, we can help patients better enjoy their personal, social, and, if applicable, working life.”

Researchers have previously assessed the effects of exercise programs on patients with less advanced cancer, finding them to benefit patients’ health-related quality of life and energy levels. However, whether these benefits also apply to patients with metastatic disease has not been rigorously tested, Dr. May said. She added that a longer exercise program may be necessary for patients with metastatic disease because their treatment usually continues for much longer periods.


Dr. May and her colleagues enrolled 357 patients with metastatic breast cancer into the PREFERABLE-EFFECT trial, a collaboration between institutions in Germany, Poland, Spain, Sweden, the Netherlands, and Australia. All participants in the trial received a physical activity tracker and generic exercise advice; 178 patients were randomly assigned to twice-weekly supervised exercise sessions for 9 months, which involved balance, resistance, and aerobic exercises (one weekly session could be performed via an exercise app during the final 3 months).

At enrollment and after 3, 6, and 9 months, the participants were surveyed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30), a comprehensive questionnaire assessing patients’ physical, mental, emotional, and financial quality of life. Additionally, the EORTC-FA12 questionnaire was used to assess multidimensional fatigue among the participants. Each questionnaire was scored from 0 to 100, with higher scores on the EORTC-QLQ-30 indicating improved health-related quality of life and higher scores on the EORTC-FA12 indicating higher levels of fatigue. Researchers also tested physical fitness using the steep ramp test, in which participants were asked to ride a stationary bike at increasing resistance levels until voluntary exhaustion.


At 3, 6, and 9 months, respectively, patients assigned to the exercise intervention had average health-related quality of life scores that were 3.9, 4.8, and 4.2 points higher than patients in the control arm. Patients who participated in the exercise intervention had EORTC-FA12 scores that were 3.4, 5.3, and 5.6 points lower (indicating decreased fatigue) at 3, 6, and 9 months, respectively, compared with those of the patients in the control arm. All differences were statistically significant.

At 6 months, patients assigned to the exercise intervention also reported significantly better scores on important EORTC-QLQ-30 subscales compared with those in the control arm, including a 5.5-point increase in social functioning, a 7.1-point decrease in pain, and a 7.6-point decrease in shortness of breath. In the steep ramp test, patients in the exercise arm reached an average maximum resistance that was 24.3 Watts (13%) higher than those in the control arm.

Dr. May and colleagues found that the 9-month intervention was not only effective but may have also encouraged longer-term compliance. “We think a 9-month program helps patients incorporate exercise into their routine,” she said. “Many patients continued exercising beyond 9 months; exercising became part of their daily lives and cancer treatment regimens.”

Based on these findings, Dr. May suggested that physicians and nurses should routinely recommend supervised exercise to patients with metastatic breast cancer and that policymakers and insurance companies should ensure cost coverage for exercise programs.

Limitations of this study include the inability to blind participants to their respective research arms, which may have motivated patients in the control arm to voluntarily increase their physical activity levels. Dr. May noted that this may have led to an underestimation of the intervention’s effect.

Disclosure: Funding for this study was provided by the European Union’s Horizon 2020 research and innovation program as part of the PREFERABLE project and by the National Health and Medical Research Council of Australia.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.